Crispr Therapeutics AG (NASDAQ:CRSP) closed Tuesday’s trading session at $40.87, days after it announced that it treated the first human subject in an early stage investigating CTX001 as a treatment for beta-thalassemia.

The company announced together with its partner Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) that the study kicked off with the first human CTX001 dose delivered. Crispr has been developing the therapy to treat a rare blood illness called beta thalassemia. Additionally, the company has been developing it as a one-time treatment.

The two firms also revealed that it has kicked off the enrollment of patients in a parallel study evaluating the treatment’s ability to combat the sickle-cell disease. The first human dosing is on track to commence towards mid-year 2018.

“Treating the first patient in this study marks an important scientific and medical milestone and the beginning of our efforts to fully realize the promise of CRISPR/Cas9 therapies as a new class of potentially transformative medicines to treat serious diseases,” stated Crispr Therapeutics CEO Samarth Kulkarni.

Crispr developed CTX001 using Crispr technology which has a variety of applications due to the efficiency of its products. However, the treatments developed using this technology might take a while before securing regulatory approval.

Crispr announces its FY 2018 and Q4 2018 financials

Crispr revealed that it generated $0.1 million in total collaboration revenue during the fourth quarter of 2018 while the revenue for the entire year ended December 31, 2018, was $3.1 million. Its cash and cash equivalents for fiscal year amounted to $456.6 million. The company also reported a $47.6 million net loss during the fourth quarter while its net loss for the year ended December 31, 2018, was $165.0 million.

Crispr also revealed that its research and development expenses for the fourth quarter were $28.8 million and $113.8 million for the year ended December 31, 2018. Q4 2018 General and administrative expenses amounted to $16.5 million and $48.3 million for the entire year ended December 31, 2018. The net loss reported in the 2018 fourth quarter was $47.6 million while the net loss for the entire FY18 was $165.0 million.

Redefine your perceptions of reality as you explore the biotech industry through the lense of a millionaire trader who has exploited the market and outperformed Wall Street by a landslide. Learn how to find small cap biotech stocks about to erupt with massive upside potential, and see how Kyle has solidified himself at the top of the market. Sign up for his next free training and see how you can do it too!